<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03199794</url>
  </required_header>
  <id_info>
    <org_study_id>241501</org_study_id>
    <nct_id>NCT03199794</nct_id>
  </id_info>
  <brief_title>Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice</brief_title>
  <official_title>Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxalta Innovations GmbH, now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study addresses the safety, utilisation and effectiveness of Obizur in the treatment of
      bleeding episodes in real-life clinical practice in Europe and the United States.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2016</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of AEs and SAEs including seriousness, severity and outcome</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>AE - adverse event, SAE - serious adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of AESIs including seriousness, severity, relationship to therapy, outcome, and treatment discontinuation</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Adverse Events of Special Interest (AESI) are as follows: hypersensitivity reactions, thromboembolic events and dose dispensing medication errors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of thromboembolic events</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Thromboembolic events include disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction and stroke.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of dose dispensing medication errors</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Dose dispensing medication erros include miscalculation of dose while prescribing (calculation of correct dose based on the participant's weight) or administration of the incorrect dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity; newly recognized anti-pFVIII inhibitor or increase in titre of anti-pFVIII inhibitors and evolution of titre over time</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obizur treatment regimen, as available</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>This may include details of the Obizur treatment regimen utilized, as available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other medication administered for haemostatic control, as available</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>This may include additional medications, treatments and procedures (other than Obizur) undertaken to control a bleeding episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall effectiveness assessment for resolution of bleeding</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Resolution of bleeding determined as either bleeding stopped or did not stop. If bleeding did not stop, a reason should be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose per infusion administered to achieve bleeding control, death or change in haemostatic treatment other than Obizur</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Bleeding control defined as all bleeding stopped.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of infusions administered to achieve bleeding control, death or change in haemostatic treatment other than Obizur</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Bleeding control defined as all bleeding stopped.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve bleeding control, death or change in haemostatic treatment other than Obizur</measure>
    <time_frame>From first administration of Obizur up to 180 days after the last administration of Obizur.</time_frame>
    <description>Bleeding control defined as all bleeding stopped.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acquired Hemophilia A</condition>
  <arm_group>
    <arm_group_label>OBIZUR participants</arm_group_label>
    <description>Participants previously treated with OBIZUR and continue to be treated with OBIZUR during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OBIZUR</intervention_name>
    <description>Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.</description>
    <arm_group_label>OBIZUR participants</arm_group_label>
    <other_name>Recombinant pFVIII</other_name>
    <other_name>Porcine Sequence</other_name>
    <other_name>rpFVIII</other_name>
    <other_name>Antihemophilic Factor (Recombinant)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A participant with acquired hemophilia (AH) must be prescribed Obizur for the treatment of
        a bleeding episode by a physician, independent of and prior to the decision to enrol the
        participant in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult participant (or legal representative) is willing to provide informed consent

          -  Participant is being treated or was treated (treatment initiation within 30 days) with
             Obizur in routine clinical practice

        Exclusion Criteria:

          -  Participant has known anaphylactic reactions to the active substance, hamster protein
             or to any of the following excipients: Polysorbate 80; sodium chloride; calcium
             chloride dihydrate; sucrose; Tris Base; Tris HCl; Tri-sodium citrate dihydrate;
             sterilized water for injections

          -  Participant has participated in a clinical study involving a medicinal product or
             device within 30 days prior to enrollment or is scheduled to participate in another
             clinical study involving a medicinal product or device at study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AKH - Medizinische Universit√§t Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum im Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <zip>10249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo</name>
      <address>
        <city>Alessandria</city>
        <zip>15100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roberto Santi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390382502174</phone>
      <email>c.ambaglio@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Chiara Ambaglio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Umberto I Pol. di Roma-Universit√† di Roma La Sapienza</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Chistolini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Saskia Schols, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

